Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Systems Biology

Background:

• Alterations in the epidermal growth factor receptor (EGFR) signaling network are key features of glioblastoma (GBM).
• EGFR-targeted therapies are a common strategy for GBM treatment.
• Current EGFR-targeted interventions show limited efficacy in GBM patients.

Purpose of the Study:

• To review key concepts and mechanisms of EGFR-targeted treatment resistance in GBM.
• To understand treatment resistance as a systems-level phenomenon.
• To inform the development of effective therapeutic options for GBM.

Main Methods:

• Literature review of systems-level mechanisms.
• Analysis of EGFR signaling network perturbations.
• Examination of adaptive capacity and resistance in tumor cells.

Main Results:

• Complex perturbations within the EGFR signaling network contribute to treatment resistance.
• Tumor cells exhibit high adaptive capacity, leading to resistance.
• Current understanding of resistance is often limited to single molecular targets.

Conclusions:

• A systems-level understanding of EGFR-targeted treatment resistance is crucial for GBM.
• Therapeutic strategies should move beyond single molecular targets.
• Focusing on network-level vulnerabilities may overcome GBM resistance and improve patient outcomes.